NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Knalysis Technologies “Knalysis”, a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) wishes to announce that it now has more than 12,000 medical cannabis patients on its software platforms representing 6% of the registered base in all of Canada. Its clinicians are providing the best care possible to these patients through Knalysis’ sister division, Marijuana for Trauma, and their eleven clinics across Canada. Coupled with Knalysis’ US client base, more than 32 million data points for medical cannabis treatment have been captured to date.
As patient count in the Knalysis platforms continues to increase by approximately 2,500 per month, it is now seeing the impact of having big data at its fingertips. This information is critical to breaking away from anecdotal evidence of the efficacy of medical marijuana. It’s simply not good enough anymore to prescribe a treatment regimen based on what “we’ve heard” works. Patients deserve better and Knalysis platforms are ensuring that they’re getting it. Knalysis Technologies’ proprietary suite of software is helping clients grow their business through major efficiency gains and improving patient outcomes by interpreting and making good use of the significant amount of data that flows through its data platforms.
Knalysis is also gaining traction with several potential new cannabis clinic clients which would add another 10,000 – 20,000 patients into its platforms by mid-year, adding 10s of millions more data points for the benefit of its analytics subscribers. All of this strengthens Knalysis’ recommendations for patient treatments and their health outcomes. This vast amount of data has led to talks with key industry reporting partners and we expect more exciting news on this front very soon. All of this progress ultimately benefits patients who have been seeking the right kind of treatment for their ailments for decades. Getting away from anecdotal evidence and proving the efficacy of medical marijuana is the key to ensuring that access to this treatment is secured for the long term.
About Knalysis Technologies:
Knalysis Technologies is part of the Canada House Wellness Group, a publicly-traded Canadian company with one of the largest networks of cannabis clinics in Canada. It envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physician, provider, and patient. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; treating a broad range of ailments and symptoms.
Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit https://www.canadahouse.ca. or www.sedar.com
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.